Inquisitiveness is a primary trait of human beings. The human brain which processes millions of thoughts in a flash of time needs to know about everything and anything around it. Human well being or fitness is one such area that has grown by leaps and bound over centuries given to the human quest to stay healthy. Specific to it is the study of diseases, their cause and effect which comes under the broad spectrum of Pathology.

1. Pioneering Solutions for a Healthier World
Dr. Ravi Gaur
Chief Operating Officer
10Most
Trusted
DiagnosticsDiagnostics
PathologyPathology Center
&
T
h
e
Volume 10 | Issue 02 | 2019

4. SME-SMO Executives Uma, Ketki
Circulation Manager Tanaji
Digital Marketing Manager Prashant Chevale
Technical Specialist Amar Sawant
Co-designer Sapana Shinde
Art & Picture Editor Karan Gaikwad
Art & Design Head Amol Kamble
Associate Designer Poonam Mahajan
Copyright © 2019 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or
transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success Media and Technology Pvt. Ltd.
Reprint rights remain solely with Insights Success. Printed and Published by Insights Success Media and Technology Pvt. Ltd.
Corporate Ofces:
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin, OH 43017, United States
Phone - (614)-602-1754
Email: info@insightssuccess.com
For Subscription: www.insightssuccess.com
Insights Success Media and Technology Pvt. Ltd.
Off. No. 22 & 510, Rainbow Plaza, Shivar Chowk,
Pimple Saudagar, Pune, Maharashtra 411017
Phone - India: +91 7410079881/ 82/ 83/ 84/ 85
Email: info@insightssuccess.in
For Subscription: www.insightssuccess.in
sales@insightssuccess.com
October, 2019
Follow us on : www.facebook.com/insightssuccess/ollow us on : www https://twitter.com/insightssuccess
Cover Price : RS. 150/-
Editor-in-Chief Pooja M. Bansal
Managing Editor
Rahul NirajContributing Writer
RNI NUMBER: MAHENG/2018/75953
Technical Head Pratiksha Patil
Business Development Leader Tejaswini Whaval
Business Development Executive Sapna Sherekar
Sneha Sinha
Business Development Manager Megha Mishra

5. From the
Editordiscussion about the healthcare sector in India is
Aincomplete without the mention of Diagnostic and
Pathology Services. To ensure complete healthcare,
harmony must be in place between the medical service
providers and the diagnostic and pathology service providers.
The two sectors complement each other and help form the
basis of a healthy society.
The diagnostic industry in India has grown with the development
of medical sciences. It has come a long way from simple blood
tests to the ultra-modern scans, hormone tests, and screening
tests. With growing health-consciousness, the demand of such
centers has also increased. With India’s growing image as a
medical tourism country, the role of reliable and certified
diagnostic centers becomes even more crucial.
The major market share of the diagnostic industry is currently
held by the unorganized centers which cater to the small and
medium-sized towns and cities. The Tier I and Tier II cities are
mostly catered by highly specialized and organized centers. This
skewed arrangement at times reflects the level of awareness
that the consumers have in these cities who demand and are
keen on utilizing best-in-class services.
On the other hand, it also represents the disparity in providing
services by the diagnostic centers who tend to have an
inclination towards monetary benefits instead of just human-
service. It certainly is true that to provide world-class services,
one needs to invest heavily in setting up the proper
infrastructure. But the other side of the coin is that unless and
until the services reach the last mile, the efficiency of an industry
is always under scrutiny.
On a brighter note, many diagnostic centers are realizing their
social responsibility and catering to the rural areas as well. They
often organize health-check up camps and utilize other means
to reach out to the lowest strata of society. The Government and
the NGOs also assist and promote the diagnostic industry to
ensure that health and diagnostic services reach all and sundry.
With the advancement in technology, easy access to
information, and a customer-centric approach, the face of the
diagnostic industry is changing for good. The customer is aware
of what is acceptable and what is not. The industry too, is aware
of the informed demands that the customer makes. The
Government too is aware of the changes required in the
regulatory scenario that can transform the industry for good.
This amalgamation hints at a future where more accurate
reports, right diagnosis and disease management, and in-turn
better healthcare costs will be made available for the masses.
The Changing
Dynamics of
the Diagnostic
Industry
Sneha Sinha

6. Genomics
Laboratory
Diagnostic Services
You can Rely On!
Cover Story
ONCQUEST
LABORATORIES
Pioneering
Solutions for a
Healthier World
Sanya Diagnostics
Delivering Quality
and Reformative
Diagnostic Services
24
36
08

7. Core Diagnostics
High-end Diagnostics,
Redefining Treatment
16
CONTENTS
Interview with Insights Success
ARTICLES
Screening Tests
Necessity and
Avoidance
Staying Alert!
OncoStem Diagnostics
Developing Innovative
Prognostic and Predictive
Solutions
28
32
Industry Insider
Facts About Stem
Cell Research That
Everyone is Talking About
CXO
20

8. o stay healthy, we are often advised regular check-ups apart from daily diet and exercise.
TThe diagnostic industry, receiving impetus from the growing health-awareness, is expected
to grow at 27.5% for coming five years. The majority share of the market is still with the
so-called unorganized sector, but the organised sector is growing and catching up fast with it.
Moreover, with increased awareness, people know the importance of accurate, reliable and certified
diagnostic centres.
This edition of Insights Success, brings to you, The 10 Most Trusted Diagnostics and Pathology
Center. These companies are ensuring world-class yet affordable services that can make India a
healthy place to be.
The Cover Story of this issue features Oncquest Laboratories, India’s Largest Cancer Diagnostic
Network which has earned its reputation for clinical excellence in the Indian market.
Also featuring in this issue are Genomics Laboratory, a well-recognized brand delivering quality
and reliable diagnostic services; and Sanya Diagnostics, which is equipped with leading-edge
technology and has been offering a wide range of radiological services since 2008.
Other significant Companies among the list are Clinical Diagnostic Center, Max Lab, NM Medical,
and Vijaya Diagnostic Centre.
The issue also highlights the viewpoints of Vipul Jain, CEO, Advancells, who shares his insight
regarding Facts About Stem Cell Research That Everyone is Talking About. The insightful interview
of Zoya Brar, Founder, CORE Diagnostics and Dr. Manjiri Bakre, Founder, OncoStem
Diagnostics, tells us how the respective companies are changing the industry. Pause to think about
the why of diagnostic services in our in-house article Screening Tests: Necessity and Avoidance
from Staying Alert.
We hope you enjoy reading this issue as much as we did while creating it!
Know Your Health
10Most
Trusted
DiagnosticsDiagnostics
PathologyPathology Center
&
T
h
e

10. Pioneering Solutions
for a Healthier
World
Everyone
talks about
Quality.
We Practice
and Deliver
Quality

11. Cover Story
Dr. Ravi Gaur
Chief Operating Officer

12. Inquisitiveness is a primary trait of human beings. The
human brain which processes millions of thoughts in a
flash of time needs to know about everything and
anything around it. Human well being or fitness is one such
area that has grown by leaps and bound over centuries given
to the human quest to stay healthy. Specific to it is the study
of diseases, their cause and effect which comes under the
broad spectrum of Pathology. It involves the study of
diseases, what causes them and often describe or define
tests and processes that need to be followed to ascertain a
particular disease. As Louis Pasteur says, “Without
Laboratories men of science are soldiers without arms”.
The origin of this science dates back to early civilization as
discovered in their records, found in several ruins. India, the
Middle East and China are credited with the initial
development, and ancient Greece is where detailed and the
present formal form of the science took shape. But the
current situation of pathology and diagnostic services in
India is no mirror to its ancient glory. While India has now
become a highly appreciated medical tourism spot with
many advanced and globally accredited diagnostic centres,
the fact remains that the infrastructure at places is severely
lacking.
India has around 100,000 plus diagnostic centres which
include pathology and radiology. As per one market report,
approx. 62% of the diagnostic market is shared by private
sector while 38% is in Govt sector. Of the entire private
diagnostic market approx. 68% is from pathology while
32% is from radiology. Also, approx. 51% of private
diagnostic market is in hospital-based centres, 47% is in
independent centres and remaining comes from small
polyclinics. Only about 20% of them are a part of the
organized pathology providers. The remaining 80% of the
industry is highly fragmented, unregulated and
unfortunately, most do not adhere to minimum standard
requirements. Though there are few pathologists owned,
standalone labs which are very well organized and high
quality driven, but they form just a fraction of total
pathology centres.
Midst all this commotion, there are a few pathology centres
which outshine owing to their high skilled workforce,
advance technology driven platforms, strong commitment
to deliver with globally accepted quality standards and with
a continuous zeal to excel.
Oncquest Laboratories Limited, Delhi is definitely one of
them. Close to two decades of its establishment, the
laboratory handles over 15000+ samples on a given day
which are processed by a highly qualified team of
pathologists, scientists, lab technicians with great precision.
Oncquest Laboratories has earned its reputation for clinical
excellence in the Indian market. Advance technologies and
global quality systems at Oncquest have ensured that it
stays ahead of the curve resulting in its association with
some of the most advanced hospitals, super specialists,
clinicians and research organizations in the country and
abroad.
The Quest to Bring the Best
Oncquest lab Aditya C Burman , started, promoted by
its journey as a part of Dabur Pharma in the year 2002,
as an advanced molecular diagnostic laboratory with an
incisive diagnosis in the field of oncology. ,In Year 2007
Mr Aditya Burman with his sharp strategic skill, high
acumen and support from few highly skilled scientific and
industry experts re-established its new independent identity
i.e. Oncquest Laboratories Ltd and made cancer diagnostic
business its main focus. Once Oncquest was fully
stabilized, Mr Burman decided to go for the bigger market
of general pathology. The company is looking to grow 25-
30% year-on-year. Dr. Ravi Gaur, Chief Operating
Officer of Oncquest laboratories, a post graduate in
pathology, joined Mr Burman in 2009 from Piramal
Diagnostics. Oncquest began expanding only in 2009, after
Mr Burman and team decided to grow aggressively in the
field of diagnostics.
“Rapid change is the defining feature of pathology! It will
come as no surprise to those in the clinical laboratory and
pathology field that the market is undergoing rapid change.
In recent decades health expectations have risen globally, a
lot being done to make diagnostics more affordable,
accessible and accurate. The proper scaling of pathology
services is key to this growth, as pathology is involved in
70% of all healthcare diagnosis. not just in India but
globally. And the Oncquest management seems in no mood
The Oncquest
Family’s vision is to
become the most
influential and appreciated
partner to those seeking
diagnosis

13. to let up. I am on an uphill track and I have to go up and
grow. I have no options”, Says Dr. Gaur, who has served in
the Indian Armed Forces for about 10 years and has over 25
years of experience in the field of Pathology and Health
care management.
Aging population and the rising prevalence of chronic
conditions like obesity, diabetes, the rise of universal
healthcare & cancer and many other factors are driving
change in the pathology market. Dr. Gaur says,“Just as
demand for laboratory services is rising, there is downward
pressure to use fewer resources. Industry consolidation is as
prevalent in laboratories as in other areas of healthcare,
with increased economies of scale expected to deliver more
test results at a lower cost. The upside is the abundance of
valuable information that flows from the life cycle of
medical testing, real-time feedback to improve process and
overall management. Pathology service providers have to
adapt to these challenges in climate where the pace of
change is likely to accelerate”.
Dr. Gaur is a strong believer of setting up advanced
platform & quality driven technologies and making them
available in the Indian market at affordable cost, a vision
that he shares with Mr Aditya Burman.
There is an upsurge of new testing methods to support
initiatives such as personalised or precision medicine, also
known as genomic medicine, and point-of-care testing.
Dr. Gaur and his team is currently working in the area of
developing diagnostic assays to support personalized and
precision medicine with genomics as a base, new point of
care or near-patient testing technologies, intending to
deliver the quality and precise diagnostic facilities at all
levels and for all sectors of the healthcare industry. He has a
strong vision to develop India specific assays and
technologies catering to India specific needs.
Today, Oncquest Laboratories have a State –of- The-Art,
NABL & CAP (College of American Pathology)
accredited Laboratory at New Delhi, is fully equipped with
advance molecular diagnostic technologies, sequencing,
and work on pharmacogenomics, companion diagnostics,
bioinformatics, biomarker studies and provide a
comprehensive menu of super specialised pathology,
including surgical and haemto-pathology, general
pathology, microbiology & various specialty laboratory
assays with unparalleled service. Oncquest s early adoption’
and utilization of genetic sequencing technologies has
resulted in many first to market assays, which have“ ”
subsequently been adopted in several treatment and
monitoring protocols. Innovation is an essential part of its
DNA.
Best in Class Services
Oncquest has one of the widest test portfolio, especially in
exploratory & end-point biomarkers, genomics, molecular
biology, surgical histology, incl IHC, haemato-pathology
and microbiology. Initially dealing with cancer diagnosis
and introducing the Clinical Face of Cancer Diagnostics in
India, today it caters to general pathology too and now
offers a varying range of customized assays, diagnostic
solutions and packages for different segments of healthcare
industry.
At present, Oncquest predominantly operates as a
diagnostic chain for ‘business-to-business model’ that caters
to hospitals and clinics, who refer patients to it for tests.
The business has seen strong growth in patient volumes in
the past few years. As it grows, it is moving ahead to ‘direct
to patient model’ specially when it comes to preventive
healthcare. Its comprehensive health check-up program is
thoughtfully structured to include all the necessary tests for
all age groups and occupation. Oncquest offers more than
500 assays spanning across the entire diagnostic field –
predictive, preventive, diagnostic, therapeutic, monitoring
and prognostic - from Oncology to Infectious diseases to
lifestyle to genetic disorders.
Apart from its super-specialized lab in Delhi, Oncquest has
40+ labs across India with over 1500 service associates and
few centers overseas too. Its hospital lab operation &
management vertical has been widely accepted. Oncquest
expertise in providing customized lab solutions to super
specialty or single specialty hospitals is widely appreciated.
Oncquest is the preferred partner for major pharmaceutical
and biotech companies seeking committed service providers
Oncquest has been
offering its central lab
services to various
Pharmaceutical and
Biotechnology companies
for their research and
commercial requirements
since 2009.
10Most
Trusted
DiagnosticsDiagnostics
PathologyPathology Center
&
T
h
e

14. For the People
Oncquest s mission,’ “Discover, Diagnose and Defend,”
speaks high about its focus on service and strength. It
believes in making healthcare and early diagnosis as
primary focus and priority instead of secondary. Dr. Gaur
points out, “If people can’t afford diagnosis and primary
healthcare what is the need of the huge advancement and
development that is taking place. At Oncquest we develop
assays and ensure that they become affordable and have a
mission to ensure that no patient returns without a
diagnosis for the lack of funds or affordability”. Mr
Burman is also a promoter of Dabur India, which has a
huge mass connect. Thus, the humane angle is inbuilt in its
DNA. Oncquest and the team makes sure that quality tests
are developed in such a way that it fits every budget and
reaches the masses.
Oncquest regularly organizes disease specific and
preventive health screening camps at highly discounted
rates and conducts awareness drives to educate people
about the good health practices. It also gives due emphasis
to early diagnosis which the team feels is the key to a
healthy life. Diseases like cancer and most lifestyle disease
can be prevented and even cured when detected early on.
Dr. Gaur says, “Its an era of Precision medicine which
works on the fundamental principle that a particular
disease gives rise to different physical symptoms in different
individuals, based on their genome structure, lifestyle,
biochemical and environmental conditions. The two people
of different ethnicity may not respond in the same way to a
drug treatment”. As they say, the ‘medical model’ of
precision medicine aims to customize the treatment based
on the three above mentioned governing factors, which
characterizes an individual’s response to the disease. The
for “Clinical Trials” (Phase I-IV) and Patient Support
Programs. Currently, it is working with almost all
Pharmaceutical companies spl with Oncology portfolios.
It has in-house qualified and well trained R&D ,
management team which actively assist the companies with
clinical study-specific kits, packaging and labelling,
seamless logistics, regulatory support and project
management tools to enhance process efficiencies. The key
members of the clinical trial team are ICH -GCP trained
with an average experience of 8-10 years.
Dr. Gaur says, ‘Oncquest’s strength lies in the quality of
the highly trained , renowned experts and skilled staff who
validate, perform, interpret and generate reports which
are as per Quality guidelines of NABL and College of
American Pathologists (CAP) and are globally accepted.
Quality is our essence, Oncquest follows best-in-class
Quality Management Systems and adheres to stringent
quality norms of NABL and CAP .”
Mission
To Discover at an early stage the condition which
afflict the populations we serve, through community
outreach and our relationships with practitioners.
To Diagnose with accuracy and reliability the
condition which are presented to us, using the
best-in-class of technology that is available;
globally.
To Defend, effectively, the population from such
diseases for the future, through education and
knowledge sharing.

15. use of system biology and panomics aids this process by
diagnosing the illness at a molecular level. Once the cause
is determined, customized medication could be prescribed
to them. Such personalized medicine moves from the ‘one-
size-fits-all’ model that doctors have previously adhered to.
While it might be expensive to customize medicine for each
individual, gathering the genetic makeup of individuals
could be useful in classifying them into groups. Such
groups, then, will have their own customized treatment.
Collecting genomic information of the population will also
aid population health studies in the future, which can help
prevent diseases at an early stage. Precision medicine can
also reduce the cost of treatment by decreasing repetitive
administration of medicine and mitigating the side-effects
associated with them. Treating an ailment on a molecular
level will help biologists understand the underlying cause
behind their occurrence and correspondingly develop
medicine to eradicate them completely. Genetic targeting
can drive the development of drugs rather than the long and
arduous trial and error procedure.
Time to Tighten the Noose
Dr. Gaur says, “There can never be any compromise on
quality, after all pathology sample is a life. We support and
provide high of quality diagnosis. Having done so much
work for the wellbeing of the society, it hurts the team to see
the spurious growth of unaccredited diagnostic centers,
especially in Tier II and Tier III cities”. While the
Government has developed stringent laws to curb them, a
lot still needs to be done when it comes to implementation.
Dr. Gaur explains that, “diagnostic tests form the base of
treatment. One wrong diagnosis doesn t only send the’
treatment off the track but also causes a setback in the form
of lost samples, precious time and even life”. While the
onus lies on the authorities and pathology centers, the
general public too should be aware of the dangers that such
unauthorized centers pose to their health. The patients
should not hesitate in asking questions about quality norms,
sample handlers and platforms for being used for testing
their samples.
There s More to Diagnosis’
Oncquest is focused on bringing early diagnosis and even
molecular diagnosis based on world-class technology
within the reach of the masses. Mr Burman, is a true
advocate and staunch adapter of highly advanced
technologies. He ensures that best technology platforms are
available at Oncquest and the R&D team is focused on
adapting these latest technologies to suit the Indian palette.
It helps to make the diagnosis, better, faster, finer and more
precise or specific. Faster turn-around -time for assays is
crucial to correct and timely diagnosis and therapy. It needs
a strong mix of biotech and infotech. Oncquest s core’
mission is to develop, perform and deliver tests that give
results within stipulated timeline.
Dr. Gaur says, “It is high time the pathologists and
scientists, now redefine themselves as Clinical Solution
Providers and not just Diagnosis Providers. It is time now
to come to the forefront and increase the usage of
communication channels with the test prescribers, treating
doctors & clinicians, as well as patients to reach a
conclusive, final, finer, precise diagnosis, which can help in
arriving and defining target therapy, resulting in better
treatment outcome. With so much advancement in
automation and diagnosis now being redefined by
molecular biology and genomics, pathologists shouldn’t just
be seen behind the microscope but come forward and
integrate with the treating clinicians, support doctors,
patients and emerge as real clinical solution provider. We
at Oncquest ensure that s its done. Integration, analytics is’
must for accurate, precise diagnosis and perfect healthcare
delivery. In this new wave of technology, you can t do it all’
yourself, you have to form alliances and have discussion .”
Dr. Gaur adds, Pathology lab is one of the largest sources of
clinical information. It is critical that laboratory
professionals have the capability to dissect and analyze, the
information to optimise their role in today’s healthcare
delivery model, and transform to lead the pathology of the
future. Laboratories vital role in the science of medicine is
now at the tipping point. The opportunities for pathology
services perhaps have never been greater – for care
collaboration, the adoption of point-of-care testing, and
Oncquest’s Quality
Management System reflects
the organization’s desire to
be ‘Best-in-Class’ and
incorporates the twin
objectives of ‘customer
satisfaction’ and ‘continual
improvement’ into the
organization’s operations.

16. driving the evolution of medicine with genomic testing. Yet
they must survive the demands of supporting an ever-
changing population and pragmatic economic pressures.
This calls for a new generation of health informatics
systems that meet the needs of a modern pathology
environment. Armed with such systems, laboratory
professionals and the pathology services they provide will
stop being the victims of market disruption – instead they
will become the key enablers of changes that will herald a
new age of medicine.
¦ Patient stratification for alternate therapy
¦ RQ-PCR assays for monitoring & Break point analysis
of CML patients
¦ RQ-PCR based gene amplification assays for profiling
of Ca. Breast
¦ Gene Sequencing – EGFR, GIST Mutation/ C-Kit
Mutation
¦ Other first to market assays
¦ RT-PCR based diagnostic assays
¦ FLT3: For AML prognostication
¦ JAK2: For Polycythemia Vera
¦ FIP1L1- PDGFRa: For Chronic Eosinophilic Leukemia
¦ NPM 1: For AML’s with Normal Karyotyping
¦ FISH method for MLL gene rearrangement
¦ Flow Cytometry based diagnosis of PNH (Paroxysmal
Nocturnal Hemoglobinuria)
¦ CD20 study: Patient stratification for Rituximab
therapy
¦ CD52 study: Patient stratification for Campath1
therapy
¦ Zap 70 testing: For CLL
¦ CD 138 testing: For Multiple Myeloma
Oncquest is the First Commercial Laboratory
in India to offer
Headquarter: New Delhi
Cities Catered: Pan India, Bangladesh, Nepal, Sri Lanka
Accreditation: NABL, CAP
We regularly train
Oncquest team members
on ICH-GCP to ensure
compliance to the guidelines
& protocol specific
parameters &
deliver quality results.

18. Interview with Insights Success
CORE DIAGNOSTICSCORE DIAGNOSTICS
High-end Diagnostics, Redefining Treatment
October 2019|16
ith an aim to reduce the gap between the Indian
Wdiagnostic industry and the rest of the world,
CORE Diagnostics was founded in 2012 by
23year old Zoya Brar- a first generation entrepreneur.
CORE’s service philosophy revolves around providing
definitive diagnostics & therapy selection in shortest
possible turnaround time with second opinion on every test.
In a little over six years CORE has become synonymous
with innovation in clinical diagnostics. Over the years,
business has grown nearly 5% on a month-on-month basis.
In the following Interview with Insights Success, Zoya, the
Founder and CEO speaks about the transition that CORE
is bringing about in the diagnostic industry.
1. Kindly brief us about the company and its initial
journey.
The inception of CORE was based on a simple
observation: while the “delivery system” of healthcare
services had caught up with the western standards, the
lack of talent availability had led to a “white space” in
high-end diagnostics. Despite the presence of handful of
large players and local labs – we were able to witness the
immense potential of advanced diagnostics. There was
dire need to supplement routine testing to address the
grossly underserved high-end diagnostic market. CORE
came to the scene in 2012 to bridge this gap by making
the advanced diagnostics procedures available, affordable
and accessible in India.
2. Brief us about you and your role in the Company?
My interest in precise disease stratification, therapy
selection and the zeal to provide definitive diagnosis
within shortest turnaround time, led me to found CORE.
My bachelor’s Degree in Sociology and upbringing in the
cities of Chandigarh, Ludhiana and Delhi made me learn
about leadership through osmosis. My skills were further
honed to perform in various roles while writing for the
Youth Parliament, organizing street plays, helping people
with disabilities and several such initiatives while in
school.
At CORE, me and my team’s modus operandi as a leader
in this space is to bring the most advanced testing
diagnostic techniques and expertise to India. As a
corollary, we are the destination for all high-end
diagnostic testing. This can be made possible only by
bringing together world-class people who share the same
vision and entrepreneurial spirit. This has been the most
challenging and the most exciting part of my journey. For
startups, it is critical for employees to be committed to an
open, transparent culture. Hence, we put a lot of emphasis
right at the start - during our interview process. Today, we
proudly stand at an attrition rate of less than 5% - in an
industry that suffers from up to 50% employee turnover.
We have a team of nearly 300 people now.
3. Brief us about the services that the company offers.
CORE has established itself as the largest, and the fastest
growing company in the high end diagnostics space with
a broader coverage test menu of several thousand plus
tests in oncology, nephrology, neurology, infectious
disease, reproductive medicine, transplant medicine, etc.
CORE offers a wide range of tests in each of these
disease segments. While our initial focus was oncology
and that’s what helped us establish our brand, we have
expanded our offering to cover all important disease
segments in molecular diagnostics/ Our most recent
addition was comprehensive test menu in nephrology.

19. Zoya Brar
Founder & CEO
October 2019| 17
“

20. 4. What are the challenges in this Sector in India?
Diagnosis sector is highly unorganized and served by a
very large number of labs focused on routine testing.
This, in and off itself is a challenge, in that it sets the
quality bar for the consumer very low.
Another big challenge is the lack of highly skilled
workforce – both on the technical side as well as the
clinical side of pathology. Lack of awareness amongst
the clinicians – regarding the importance and role of
diagnostic, prognostics, and predictive tests used to be a
challenge but I believe CORE successfully addressed
that in the first two years of its existence.
Price sensitivity is always a challenge in the Indian
market.
5. What are the unique propositions that the centre
offers giving it an edge over competitors?
We stand out in many ways. First, the panel of experts in
the US is world class and includes some of the top names
in Academic Medicine. Second, having investors based
in the Silicon Valley, Boston, London and Mumbai gives
us tremendous access and exposure. Our work culture is
transparent with a flat hierarchy.
Most importantly, we stand out on the label of
INNOVATION. We are innovative – in everything we
do. And we are perceived as such.
6. Please share the latest technology that the centre is
utilizing to offer better services.
We have brought in innovation in various dimensions.
For instance, we have the broadest menu of high-end
molecular and genomic diagnostics in Cardiology,
Oncology, and Reproductive Medicine. Identifying the
need gaps in the sector, we are focused on scientific
breakthroughs in three general areas – genomics,
informatics, and massive reductions in the cost of testing
which is the utmost need in the sector.
Not too long ago, CORE joined hands with Guardant
Health to launch the world’s leading comprehensive
liquid biopsy test in India for patients in advanced stage
of cancer. Last year, CORE added another feather in its
cap by achieving the shortest turnaround time from 7
days to 5 hours through the COREprime technology. A
similar partnership was set up with Promega biotech to
bring in technology that helps in the selection of the most
effective clinical intervention.
7. How does the firm intend to handle its Societal
Responsibility? Please mention any special charity or
program as such.
Preventive healthcare still has a long way to go before it
becomes mainstream anywhere in the world, even more
so in India. Towards this goal, CORE has established a
genetic counseling program to spread awareness and
provide counseling to patients and guidance to clinicians.
We routinely conduct CMEs for clinicians to make them
aware of the newest developments.
Finally, as a part of societal responsibility, we also offer
our services free of cost for those who most need them.
October 2019|18

21. Headquarter: Udyog Vihar, Gurugram
Ÿ Cities Catered: 150 + cities and 12
International markets
Ÿ Quality Certifications: National Accreditation
Board for Testing and Calibration
Laboratories (NABL)“
8. What are the company’s views regarding the spurious
growth of uncertified and illegal centres that crop up?
Back in 2012, spending nearly six months interviewing
clinicians and fellow diagnosticians to understand the
pain points of our industry. Even then it was clear to me
that the chasm between those that were providing reliable
results and everyone else was extremely wide. There are
nearly 1,00,000 diagnostic labs in the country, and many
of them lack the stringent quality systems that are
essential to achieve consistency, accuracy and timeliness
of test results. Less than 5 percent laboratories are
authorized by the National Accreditation Board for
Testing & Calibration Laboratories (NABL).
9. Brief us about the company’s future perspectives.
We see our broader agenda as re-shaping the diagnostic
industry – in a manner that it turns into the central pillar
of healthcare delivery. At present, we are actively
working at expanding our reach through various
partnerships with Government, Pharma, and Health tech
companies Also, we are adding new clinical areas
enabled by latest, cutting-edge technologies in whole-
genome sequencing, proteomics, and more recently,
metabolomics.
We have already become the partner-of-choice for many
Pharma company for conducting clinical trials, and we
expect our business to grow rapidly in this segment.
Finally, we believe we will soon be viewed as a Clinical
Data Science company, in addition to being a best-in-
class clinical laboratory.
October 2019| 19

22. he human body is a complete system in
Titself. Each organ, individually and
collectively, works day in and day out to
keep it functioning smoothly. But as it is with any
other system, our body is also prone to snags and
break-downs that are commonly called as
diseases.
The term disease is often defined as a “disorder
of structure or function, especially one that
produces specific symptoms or that affects a
specific location and is not simply a direct result
of physical injury.” So any kind of deviation or
disorder from the normal working, is termed as
illness, sickness or disease. And once the root
cause is identified, adequate treatment is given to
restore the health or the normal working
condition of the body. The role of accurate
diagnostics is of prime importance here, because
an error or shortcomings in diagnosis can lead to
unwanted effects.
Staying Alert!
SCREENING
TESTS
Necessity and Avoidance
October 2019|20

23. October 2019| 21

24. Reading the Early Signs
With the fierce development in medical science and technology, it is now possible to conduct tests that can warn people
about the onset of a certain disease. Screening tests, as they are known, are done to detect potential health disorders in
people who currently show no symptoms of the disease. The objective here is early detection, to reduce the risk of disease
through lifestyle changes and/or surveillance. In severe cases, early detection helps to treat the disease more effectively.
Screening tests, though not 100% accurate are valued for their ability to detect potential problems, and minimize unclear,
ambiguous, or confusing results. They are generally recommended for people at high risk for disease, or very rare diseases.
Some of them being:
Cholesterol Monitoring – A waxy substance found naturally in our body and also in the food that we eat. It is required by the
body in a moderate amount and when the levels increase, the risk of cardiovascular diseases increases too. A timely detection
helps by making lifestyle changes, though it doesn’t completely rule out the risks.
Cancer Detection – Tests like pap test(smear), prostate-specific antigens, mammography, etc are done to rule out the chances
of developing cervical, prostate and breast cancer respectively. Cancer, as we know, can be controlled when detected early.
How much is too much?
Screening tests and search engines have put information in the hands of the common man. The result is a revolution that
borders on discombobulation. People are going in for screening tests, not because their medical practitioner said so, but
because the nearest diagnostic center was offering a huge discount. And yes, their neighbor or a close family-friend thinks it
is important to do so. Often people rush into treatment at the smallest pretense without bothering to understand the effects of
it. This has given rise to the phenomenon of over-diagnosis and over-treatment.
The diagnostic industry is handling out DIY kits to detect diseases. While this might be useful, they argue, it also brings with
it unnecessary worry. As soon as people see their values slightly different from what is considered normal, they jump to the
conclusion that they are sick and need immediate treatment. The fact that the treatment might take a toll on their financial,
mental and physical condition is lost in their conviction of being ill.
Drawing the Line
Prevention, they say, is better than cure. Screening tests or early diagnosis are a way to incorporate the habit of prevention
into our lives. But like everything else, this too needs to be practiced with caution. These tests are developed to ensure that
the population remains healthy. Understanding the fine divide between when to and when not to go for treatment is
important. What can be done using grandma’s remedy need not go through an all-out medical procedure. Being informed is
good, but this information should come in with a warning or suggestion on when to act and when not.
Our body does a lot for us, and screening tests are a way we can help our bodies in their work. While acting on these test
reports is essential, so is listening to our own body and a certified medical practitioner who is trained and has vowed to help
humanity in staying healthy. The key here is finding the right balance between screening tests, their results and the need to
undergo treatment. The level of treatment required should always be ascertained by a medical practitioner to get the best
results.
- Sneha Sinha
October 2019|22

26. n the Diagnostics and Pathology industry, the name
IGenomics Laboratory is synonymous to quality and
reliable diagnostic services. It is a well-recognized
brand committed to helping improve the quality of patient
care by providing reports that support clinical decision-
making for doctors.
The Harbingers of Evolved Testing
The odyssey of Genomics started when the Diagnostics and
Pathology industry were on a lookout for newly evolving
testing methods like Molecular Diagnostics and
Sequencing. The team of Mr. Pritpal Singh, Dr. Jasneet
Kaur and Dr. Upinder Singh translated their zeal to make
esoteric testing affordable and accessible across the country
into Genomics Laboratory. The idea stemmed from Dr.
Jasneet’s vision to offer investigations that deal with
Syndromic or symptoms testing and help the treating
clinicians arrive at the final diagnosis more quickly and
affordably.
Genomics started with a small setup in the buzzing hub of
Labs and Diagnostics Centers in West Delhi.
The acumen of Dr. Upinder Singh and team led to
astounding growth in terms of territorial coverage across
India, wider test menu catering to all Specialties and
financial stability. The initial days were tough as it had to
implement new custom made LIS and scout for the new
location due to increased volumes of Samples day by day.
But nothing proved deterrent to its endeavour to promote
Molecular Test Menu to Specialized Medical Fraternity. It
GENOMICS
LABORATORY
was soon treading towards a well organized and planned
mission to be India’s Fastest growing Molecular Testing
Laboratory.
Key Services
Genomics offers a broad range of clinical tests and profiles.
The profile comprises of a variety of test combinations
which are specific to a disease or disorder as well as
wellness profiles that are used for health and fitness
screening. It has developed several tests in-house and also
filed patents for a few. Other work includes next-generation
sequencing to help doctors personalise medicine for cancer
patients and genetic diagnosis and screening to assess if an
expecting mother’s child is at the risk of any serious genetic
disease.
Genomics is one of the very few diagnostic providers in the
country who offer end to end solutions. Of special note is its
End to End Logistics solutions of samples pickup PAN
India that helps it maintain and monitor the integrity of the
samples through cold chain logistics. It has painstakingly
developed the system leveraging the more than 20 years of
experience in the diagnostics industry, of its co-founder
Pritpal Singh.
Key Service Areas
1. Specialized Diagnostics: Molecular Biology, Flow
Cytometry, Gene Sequencing, Surgical Pathology and
Immunohistochemistry (IHC), Cytogenetics, NGS,
Multiplex PCRs etc.
Diagnostic Services You can Rely On!
October 2019|24

27. 2. Routine Diagnostics: Hematology, Biochemistry,
Clinical Pathology, Microbiology, Immunoassays,
ELISA, CLIA, HISTOPATHOLOGY etc.
3. Hospital Lab Management: Partners with Hospitals to
optimize Lab Operations.
4. Clinical Trials: Partners Pharma Cos, CROs for trials &
Patient Support Programs.
Striving for Better – Always
The pathology industry works on four basic principles:
1. Formidable TAT (Turn Around Time) for the Reports.
2. Reliability/Quality of the Test Results.
3. Sound Logistics so that the samples reach processing
Lab/centre on time thus enabling faster Delivery of Test
results.
4. A customer Care which is consistently good in quality.
GENOMICS consistently endeavours to adhere to these 4
basic principles and thus has an edge over the competitors.
Apart from these, it also relies on its information
technology systems to ensure efficiency and improved the
productivity of its operations. It also helps in monitoring its
network’s performance, refining resource allocation,
tracking consumption patterns. The main components of its
technology architecture include the following:
Laboratory Information Management System (LIMS) – It
manages the core workflow from patient enquiry to
specimen collection process and from testing to reporting. It
stores and manages all clinical laboratory data, including
patient demographics, reference details and medical
information and more.
Systems Applications and Products in Data
Processing(SAP) – SAP maintains records for accounts
payable, accounts receivables and inventory, as well as
banking and general ledgers. It also allows us to better
manage its finances, inventory and purchasing through the
provision of real-time data from several locations.
Privacy and Security of User Data – Genomics stores
patient data on its data servers, with strong authentication
mechanisms, maintained by its information technology
staff.
We’ve developed
tests that help us provide
the final diagnosis
using just a single
investigation covering a
multitude of diseases helping
in early diagnosis
and treatment
initiation.
“
Dr. Upinder Singh,
Director
10Most
Trusted
DiagnosticsDiagnostics
PathologyPathology Center
&
T
h
e
Pritpal Singh
GM Sales
October 2019| 25
“

28. Data Collection and Analytics – Data collected through the
systems and operations are analyzed time and again to
determine, for example, seasonal trends of diseases, ways to
improvise diagnostic services, preventive and related
healthcare services best suited to the community, or
information related to tests that are commonly bundled by
our patients.
Challenges in the Industry
Team Genomics feels that the diagnostic laboratories
industry in India is poised for strong growth because of
rising demand for healthcare but lack of regulation remains
a major concern, considering the risks it poses to patients.
Dr Upinder explains, “There is no stratification of labs and
there is lack of awareness. People don’t know the difference
between an accredited lab and any other lab. That is
because there is no legislation around it.” He further adds,
“Accreditation is a voluntary process which should be
made mandatory. Though it is not proposed to be enforced
on clinical establishments including laboratories but Under
the Clinical Establishments Act, the effort of the
government is to enforce standard treatment protocols,
ensure adherence to minimum standards and range of rates
of medical/diagnostic procedures, which is essential to
make proper healthcare available by ensuring affordability
and accessibility to the citizens of the country.”
The company feels that the real menace are the labs which
have a poor quality control system and are in no position to
give assurance on the reliability of test to their customers.
The government should formulate a ‘robust policy’ in the
interest of patients for regulating the functioning and
opening of pathological laboratories and to constitute
appropriate authority for regular checking of such
laboratories. One cannot and should not allow
mushrooming of path labs managed by unqualified
professionals and non-calibrated testing equipment.
Spreading Out
Genomics has a PAN India presence and while starting a
new center it draws a detailed business plan which includes:
Ÿ Market Analysis in terms of Strengths, Weaknesses,
Opportunities and Threats and viability of the Center
Ÿ Location of the centre which should be visible and
accessible to patients or clients.
Ÿ Logistics need to be defined so that samples reach on
time and reports served with minimum TAT.
Ÿ Sales Staff to be sorted out to help grow the business
organically.
Ÿ The business model should be scalable.
Future Prospectives
Genomics envisions becoming the country’s first choice for
molecular healthcare services at affordable prices. It aims to
become a network of highly automated and sophisticated
Molecular diagnostic laboratories without any compromise
on accuracy, quality, technology, standards, customer
contentment and morals. Having spread its wings across
India already, it is looking to enter the markets in
neighbouring countries this very year and hopes to derive a
sizeable portion of its revenues from these markets in the
coming years.
October 2019|26

30. or the general mass, the word Cancer elicits fear; of
Fthe unknown and of certain death. Cancer indeed is a
complex disease which not only affects the patient,
but the complete family. It doesn’t only affect an
individual’s health, but other aspects like social,
professional and financial life as well.
When Dr. Manjiri Bakre lost a dear one to the disease, she
was determined to know what exactly went wrong.She
founded OncoStem Diagnostics in 2011 with a vision to
develop tests that help to identify patterns of cancer
recurrence risk. An understanding of these patterns ensures
that patients receive personalized therapies and treatments
that are best suited to their condition.
The following Interview with Dr. Manjiri highlights the
need of understanding the tumor biology in optimizing
therapy for cancer patients.
1. Kindly brief us about the company and its initial
journey.
I founded OncoStem in 2011, after being moved by the
death of a close friend due to breast cancer. She died
despite being diagnosed with early-stage disease, maybe
due to a limited understanding of the tumour biology
driving the disease. Companies in the West were
developing tests that could analyze tumour biology and
determine the risk of relapse in patients with early-stage
breast cancer patients. These tests could help personalize
a patient’s treatment plan based on that patient’s
individual risk of relapse. Since these tests are very
expensive, I approached doctors in India and pitched my
idea of developing a home-grown and affordable version
of such a test.
2. Brief us about you and your role in the Company?
I am the Founder and CEO of OncoStem Diagnostics. I
wear multiple hats in OncoStem and enjoy managing
just about every aspect of OncoStem. There is really
nothing beneath me or nothing that I would not want to
do. If I do not know about some task I will read up, talk
to the experts and learn it to do it well. I have started
right from setting up the laboratory infrastructure,
purchasing consumables to hiring and training first 2-3
employees. I do fund raising, look into finances, take
care of Scientific aspects, legal and patenting, plan out
new tests and research avenues. Speaking with
clinicians for marketing the test, attending conferences
to bring in more collaborations, marketing the test,
finding new partners to work with us within India and
abroad. I have a team of 30 very capable people now
and they help me many aspects.
3. Brief us about the services that the company offers.
OncoStem has developed a prognostic test called
“CanAssist Breast”, early-stage hormone receptor
positive breast cancer patients. It makes customized
treatment possible by analysing the patients tumor in
depth and providing a patient specific report. CanAssist
Breast categorizes patients based on the risk of cancer
recurrence clearly as either ‘low or high’ with no grey
area in between. This clear distinction of patients based
on risk of cancer recurrence allows doctors to devise
treatment plans that are in tune with the prognosis,
maintaining a balance between the benefits and side
effects. Patients who are at low risk of relapse can
potentially avoid chemotherapy and its associated side-
effects while patients who are at high risk of relapse
would benefit from the addition of chemotherapy to
their treatment regimen.
4. What are the challenges in this Sector in India?
Conducting validation studies in India can be challenging
because the clinical trial framework is not as well
established as developed countries. I must have
approached 50-60 hospitals to work on developing and
validating CanAssist Breast, which ultimately led to 10
hospitals signing up. There are many reasons for this – 1)
ONCOSTEM
DIAGNOSTICS
Developing Innovative Prognostic and Predictive Solutions
October 2019|28

31. Dr. Manjiri Bakre
Founder & CEO
Interview with Insights Success
October 2019| 29

32. Ÿ Headquarter: Bangalore, India
Ÿ Cities Catered: pan-India
Ÿ Quality Certications: ISO 13485, CE Mark,
CAP accreditation
one is that the doctor-patient ratio in India is well below
the developed world. Each oncologist in India sees many
more patients per day leaving them with little time to
focus on research studies. 2) Lack of documented patient
records and follow-up also makes it difficult to conduct
studies that require patient history. Patients often move
back to their hometowns after treatment and are lost to
follow-up. 3) Lack of enforcement and encouragement
of importance of research studies, clinical trials, detailed
documentation from government and regulatory
authorities. If they enforce and encourage these
activities, we can develop far more world class
diagnostics, drugs and medical devices than currently
doing.
5. What are the unique propositions that the centre
offers giving it an edge over competitors?
Our product CanAssist Breast is the only test to be
validated on Indian patients. Competitors are developed
and validated in Western countries, on Caucasian
patients. Caucasian breast cancer patients tend to be older
and post-menopausal at diagnosis, whereas their
counterparts in India tend to be younger and pre-
menopausal. Our USP is that we have taken this into
consideration right from test development. Our offering
is the only product to have data on Indian patients. We
are also the most affordable offering in the market today,
giving us another edge over prohibitively expensive
Western tests. Finally, our trun around time is the shortest
so we report within 8-10 days compared to 3 weeks taken
by some of the competing tests.
6. What are the key points that you consider while
opening a new centre?
Quality is key. Given the impact on a patient’s health, all
medical testing should be done in a quality controlled
environment by qualified and well trained personnel. The
proper accreditations should be in place, as this ensures
that laboratories follow a quality management system
and face regular quality audits. At OncoStem
Diagnostics, we strive to maintain the highest quality.
Our laboratory has been audited and certified by National
Accreditation Board for Testing & Calibration
Laboratories (NABL) and College of American
Pathologists (CAP) for upholding quality systems as per
ISO 15189. Our laboratory also participates in various
external quality assurance schemes including the one run
by the National Cancer Grid based out of Tata Memorial
Hospital in Mumbai. Our test CanAssist Breast is CE
marked, making it eligible for sale in the European
Union.
7. Please share the latest technology that the centre is
utilizing to offer better services.
OncoStem flagship product ‘CanAssist Breast’ test uses a
cutting edge machine learning-based algorithm to predict
the risk of recurrence for patients. Machine learning is
known to be a more advanced tool to develop prognostic
tests where patterns of patient information need to be
understood and analysed. We are also working on full
automation of the test, including digital pathology, so that
it can be sold as a kit and performed in a decentralized
manner in the future. This will reduce the turn around
time and also allow the test to be performed in a standard
manner irrespective of which laboratory is doing the test.
8. How does the firm intend to handle its Societal
Responsibility? Please mention any special charity or
program as such.
OncoStem partners with key opinion leaders in oncology
and supports them in conducting breast cancer screening
camps and other awareness programs. We do this through
doctors to ensure that patients get the right advice from
qualified medical professionals. We are looking to reduce
the price of the test for public sector institutions so that
more and more patients are benefitted. We are also
looking partner with NGO’s who work in the breast
cancer space and can support patients in their treatment
journey.
9. What are the company’s views regarding the spurious
growth of uncertified and illegal centres that crop up?
This can be really damaging to patients as accurate
diagnosis of disease is the first and most important step in
their treatment journey. Incorrect test results can have a
life-changing and often irreversible impact on the health
of a patient. Major surgeries and treatments are planned
based on the result of medical tests. Unfortunately, only
1,038 out of 1,00,000 labs are accredited by National
Accreditation Board for Testing & Calibration
Laboratories (NABL), which is less than 5% of all labs in
India. Ideally, all labs should be accredited by the
national body as is the case in developed countries. To
ensure affordable testing in India, we should look at other
measures that can lead to lower costs rather than
compromising on quality.
10. Brief us about the company’s future perspectives.
OncoStem is working to globally validate its “Made-in-
India” test CanAssist Breast, by undertaking studies
across multiple continents. We are also working with
pharmaceutical companies to develop targeted drugs
based on the learnings from CanAssist Breast, which can
help treat those patients who don’t respond to
conventional therapy. And finally, we are also working to
build a pipeline of tests that can personalize treatment for
other cancers like ovarian cancer.
October 2019|30

34. Vipul Jain
CEO
October 2019|32

35. Vipul Jain, CEO, Advancells, is a
serial entrepreneur who specializes in
spotting business opportunities in the
inchoate stages. An MBA from
Rochester Institute of Technology,
New York, Vipul established
Advancells in 2013. The research-
based company focuses on providing
cutting-edge Stem Cell Therapies for
patients with life-threatening
diseases and also targets lifestyle
diseases with anti-aging technology.
About the Author
FACTS ABOUT
THAT EVERYONE IS TALKING ABOUT
Stem cells are unspecialized cells of the human body. They can
separate into any cell of a living being and have the capacity of
self-replenishing. Undifferentiated cells exist both in embryos
and grown-up cells. There are a few stages of specialization.
Formative strength is decreased with each progression, which implies
that a unipotent cell cannot separate into several types of cells as a
pluripotent one.”
For thirty years, scientists and researchers have studied the origin,
potential, and other aspects of stem cells. While some believe that all
the hard work is not going to reap some benefits, for others it is just the
beginning as regenerative medicine can do much more.
In 2006 when adult stem cells were discovered, no one could have
thought how these could be reprogrammed to work like embryonic
stem cells and give solutions to several chronic illnesses around the
world. It is an achievement that scientists have been able to regularly
treat concerns like Parkinson’s disease, Alzheimer’s, cardiovascular
diseases, retinopathy, hair loss, and more.
Stem cells have several features. To start with, the self-renewing
capability is the trademark property of stem cells in regular and
diseased tissues. Second, the cells that keep on partitioning over
extensive periods are substantially more prone to gather changes that lead to neoplasia and
different ailments. Third, the self-renewal of stem cells is constrained by flagging pathways in
various tissues. Every one of the characters of stem cells advance leads to new research. In
particular, undifferentiated cells can be utilized in new drug tests. Each analysis of living tissue
can be performed securely on explicitly separated cells from pluripotent cells. In the event that
any unfortunate impact shows up, ingredients can be changed until they arrive at an adequate
degree of viability. The medication can enter the pharmacological market without hurting any
living being. Notwithstanding, to test the medications appropriately, the conditions must be
equivalent when looking at the impacts of two medications. To accomplish this objective,
specialists need to oversee the differentiation procedure to create unadulterated differentiated
cells.
In any case, the way to progression isn’t as smooth as it ought to be. Among the disadvantages,
one of the primary points is that this kind of research requires gathering embryonic stem cells.
Industry Insider
“
October 2019| 33

36. Embryonic stem cells are obtained by destroying an unborn
organism when collected, which to some is an immediate
choice to end a human life. No measure of medicinal
research should come at the cost of human life regardless of
the number of individuals who could be possibly treated
from procedures created from this exploration.
Some disadvantages that need experts’ attention are:
• The medications created from stem cells are experimental
in nature. The best treatment presently is hematopoietic
stem cell transplantation (HSCtx). They are 90%
compelling and around 50,000 transplants happen every
year.
• The expense of a single stem cell treatment in the United
States is normally about $10,000. A few facilities have
discovered approaches to decrease this expense by up to
20%. Outside of the United States, the expenses can be as
high as $100,000. The expense of producing an
embryonic cell is up to $2,000 per occasion.
Administrations rendered to take undifferentiated stem
cells may not be incorporated into the treatment cost and
could be a few thousand dollars. What’s more, since stem
cell medications are experiments in many cases, medical
coverage plans, and government-offered advantages don’t
go for the most part give access to them.
• The ethics of undifferentiated stem cell research will
consistently put constraints on the medicinal capability of
this examination. People must settle on their own how
they will react to the morals of this examination. Is it
allowed to modify adult stem cells or embryonic stem
cells? What are the outcomes of destroying a developing
life to get undifferentiated cells, regardless of whether that
embryo would have been disposed of? A few people will
feel the whole procedure is dishonest and that can keep
creating obstacles in the research.
Although the demonstrated advantages of adult stem cell
research are to some degree restricted by current scientific
technologies, the future capability of this procedure keeps
on motivating many scientists and doctors across the world.
Numerous chronic ailments, for example, birth defects or
disease, are brought about by inappropriate differentiation
or cell division. As of now, a few undifferentiated organism
treatments are conceivable, among which are medicines for
spinal cord damage, cardiovascular breakdown, retinal and
macular degeneration, ligament cracks, and diabetes type 1.
Undifferentiated cell research can further help in a better
understanding of stem cell physiology. This may bring
about discovering better approaches for treating chronic
ailments.
October 2019|34

38. he human body, as we know, is prone to infections and diseases. A healthy lifestyle sure wards off many forms
Tof illness, but most people do fall sick. While the doctor is the first person they go to, the role of diagnostic
service providers is equally important.
In tandem with the doctors, these diagnostic service providers, clinicians or pathologists help in investigating the root
cause of a disease. Once a definitive answer is derived, it gets easier for the doctor to prescribe the accurate medicine.
As such, the onus lies on the diagnostic centers to provide a timely and accurate diagnosis.
SANYA
DIAGNOSTICS
Delivering Quality and Reformative
Diagnostic Services
Mr H L Gupta
Promoter
October 2019|36

39. Equipped with leading-edge technology since 2008, Sanya
Diagnostics, established as a Centre of Excellence in
radiology, has been offering a wide array of radiological
services. Sanya group has multiple operational diagnostic
centers across the country to provide diagnostic services of
the highest level.
Over the 11 years of its operations, the company has
continuously invested in advanced diagnostic systems
sourced from world leaders in their respective fields. Its
timely investments in advanced IT systems like PACS has
facilitated across the board access of cases and facilities for
online reporting and expert opinion.
Services You can Rely On
Headquartered in the capital city of New Delhi, Sanya
Diagnostics and its associates have more than 30 diagnostic
centres across India spread over all types of city / towns –
Metro, Tier 1, Tier 2, Tier 3 viz Ahmedabad, Baroda,
Bhavnagar, Bhopal, Jabalpur, Jamnagar, Rajkot, Surat etc.
Some of these centers are operational on Public-Private
Partnership (PPP) basis with the Govt.of Gujarat, the Govt.
of Madhya Pradesh etc.. The company has, on its panel, a
large team of fully qualified full-time Radiologists,
Technologists and support staff who ensure quick
turnaround time. The centers have well-trained Customer
Relationship Management teams who make it their mission
to lay ample stress on empathy and hand holding, making
patients feel comfortable and at ease right at the reception
desk.
The diagnostics facilities provided by Sanya Diagnostics:
• Magnetic Resonance Imaging (MRI) – All Special
Procedures including Cardiac MRI, MR Mammography,
MR Spectroscopy, Tractography, Functional imaging, etc.
• Computed Tomography – CT (Coronary Angiography
etc.)
• Ultrasonography
10Most
Trusted
DiagnosticsDiagnostics
PathologyPathology Center
&
T
h
e
“
Our endeavor is to provide
quality and reliable
Diagnostic Service at an
affordable cost, and to
constantly upgrade
ourselves to meet the
demands of the
Clinicians and Patients
“
• Color Doppler
• Dexa
• Mammography
• Digitalized X-Ray(500 mA)
• Non-Invasive Cardiology (TMT/ECHO/HOLTER)
• Lab Investigations
• Exclusive HEALTH CHECKUP packages
The Promoters
Mr. H.L. Gupta:
Mr. Gupta is a businessman of repute with vast
experience in various Industries (Textile, Garments,
Real State, Medical Imaging etc). He is a veteran in
the field of diagnostic imaging services and has been
associated with diagnostics for 03 decades. He set his
foot in providing diagnostic imaging services (CT-
Scan & MRI) by establishing his first diagnostic center
in 1989 at Moolchand Hospital, Delhi. His 30 years’
October 2019| 37

40. track record speaks volumes of his ability to envisage,
build and scale a business. His vision and passion have
helped Sanya Diagnostics grow multi-fold.
Mr. Roop Madan:
Mr. Madan is a successful serial entrepreneur and also
has a considerable business interest in Import-Export,
Real Estate (eg. Godrej Noida Project), Hotels (eg
Marriot- Gurgaon), Infrastructure & IT industry. He is a
man of business vision and has been the key factor in the
entire business and financial developments of the group
business. Mr. Madan is also associated with various
charity, business & industrial associations and
organizations.
Aiming for Even Better Services
Sanya Diagnostics has been serving the society with the
help of more than 350 trained staff members who make
the diagnostic process a sail through experience for
patients. Its packages are custom designed for client
needs based on Age, Gender and any specific
requirements.
Sanya Diagnostics had received – “Best Diagnostic
Centre in International Region” Award from Socrates
Committee of European Business Assembly , U.K.
Also received the “Best Diagnostic Services Company of
the Year 2019” from Global Leaders Awards at Dubai.
Sanya Diagnostics’ future endeavors will ensure that it
surpasses patient expectations through exceptional
service quality and outstanding clinical outcomes.
www.sanyadiagnostics.com
Info@sanyadiagnostics.com
October 2019|38